Previous 10 | Next 10 |
Analysis of Open-Label Portion of Ongoing Phase 2 Trial of GEO-CM04S1 Presented at 23rd Annual World Vaccine Congress Atlanta, GA - ( NewMediaWire ) - April 06, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines ...
80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model Atlanta, GA - ( NewMediaWire ) - April 05, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentat...
New data from the ongoing Phase 2 trial of GEO-CM04S1 to be presented Atlanta, GA - ( NewMediaWire ) - March 30, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announ...
2023-03-23 20:15:22 ET GeoVax Labs, Inc. (GOVX) Q4 2022 Earnings Conference Call March 23, 2023 04:30 PM ET Company Participants Gabrielle DeGravina - CG Capital David Dodd - Chairman, President & CEO Mark Reynolds - CFO Kelly McKee - Chief Medical Office...
Company Expands Ongoing Clinical Trials and the Breadth and Capacity of Its Novel Vaccine Platform Technology ATLANTA, GA, March 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vacci...
Dr. Diamond and City of Hope COVID-19 Vaccine Team Nominated for Best Academic/Research Team Award Atlanta, GA - ( NewMediaWire ) - March 15, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against solid tumor canc...
Conference call to be held Thursday, March 23, at 4:30 p.m. Eastern Time Atlanta, GA - ( NewMediaWire ) - March 09, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced tod...
Company Progress to be Discussed During Analyst-Led Fireside Chat ATLANTA, GA, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today a...
Data Presented Indicated Very High Levels of Immunogenicity of the Combinational Therapy Atlanta, GA - ( NewMediaWire ) - February 27, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today ann...
Mobile Community Clinical Research Facility to be Deployed in California Atlanta, GA - ( NewMediaWire ) - February 15, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, and EmVenio Research, a...
News, Short Squeeze, Breakout and More Instantly...
ATLANTA, GA - ( NewMediaWire ) - July 11, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a cert...
GeoVax Labs, Inc. (NASDAQ: GOVX) is one of today's top gainers. The company's shares have moved 20.05% on the day to $3.02. GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ank...
Award of BARDA Project NextGen contract represents a significant milestone event; total value of award to GeoVax and its CRO partner total approximately $367-388 million BARDA-funded 10,000-participant Phase 2b study will evaluate and compare GeoVax’s ...